Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 1, 2006
- Accepted for publication March 10, 2006
- Published online June 1, 2006.
Copyright & Usage
© 2006 by Society of Nuclear Medicine
Author Information
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Comparison of Measurement and Prognostic Power of SUV Between High-Definition and Standard PET Imaging in Non-Small Cell Lung Cancer Patients
- Whole-Body Parametric Imaging of 18F-FDG PET Using uEXPLORER with Reduced Scanning Time
- Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions
- Performance of Digital PET Compared with High-Resolution Conventional PET in Patients with Cancer
- Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization?
- First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma
- Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
- Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network
- Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer
- Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study
- Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging
- Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials
- 89Zr-anti-{gamma}H2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma
- Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials
- Repeatability of SUV in Oncologic 18F-FDG PET
- Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort
- Getting the Most out of 18F-FDG PET Scans: The Predictive Value of 18F-FDG PET-Derived Blood Flow Estimates for Breast Cancer
- Accuracy and Precision of Partial-Volume Correction in Oncological PET/CT Studies
- Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size
- Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies
- Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy
- Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
- Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials
- Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials
- 18F-FLT PET Evaluation of Radiation Response
- FDG PET-CT in follicular lymphoma: a case-based evidence review
- Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
- The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
- Sarcoma Mid-Therapy [F-18]Fluorodeoxyglucose Positron Emission Tomography (FDG PET) and Patient Outcome
- Early Predictive Value of Non-response to Docetaxel in Neoadjuvant Chemotherapy in Breast Cancer Using 18F-FDG-PET
- Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response
- Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift?
- Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab
- Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging
- Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials
- Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab
- Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value
- 18F-FDG PET as a Surrogate Biomarker in Non-Small Cell Lung Cancer Treated with Erlotinib: Newly Identified Lesions Are More Informative Than Standardized Uptake Value
- 18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
- Assessment of Valvular Calcification and Inflammation by Positron Emission Tomography in Patients With Aortic Stenosis
- Mutatis Mutandis: Harmonize the Standard!
- Imaging in Sarcoma
- Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT
- 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
- Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients: FDG-PET and CT Imaging Study
- Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants
- FDG-PET as a Potential Tool for Selecting Patients with Advanced Non-Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy
- Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib
- PET and PET/CT of the Neck Lymph Nodes Improves Risk Prediction in Patients with Squamous Cell Carcinoma of the Oral Cavity
- Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team Survey
- Standardization of Quantitative Imaging: The Time Is Right, and 18F-FDG PET/CT Is a Good Place to Start
- Variations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users
- Monitoring Response to Antiangiogenic Therapy in Non-Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma
- Imaging Atherosclerotic Plaque Inflammation by Fluorodeoxyglucose With Positron Emission Tomography: Ready for Prime Time?
- SUVs: Always a Good Choice?
- Imaging in drug development: will it deliver on the promise of personalised medicine?
- Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
- A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
- Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
- Frontiers of Biomedical Imaging Science 2009: Workshop Report and Research Opportunities
- Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies
- Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
- 18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy
- Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience
- Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans
- Comparison of Imaging Protocols for 18F-FDG PET/CT in Overweight Patients: Optimizing Scan Duration Versus Administered Dose
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- Standards for PET Image Acquisition and Quantitative Data Analysis
- Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET
- Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer
- FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas
- Measuring Response with FDG-PET: Methodological Aspects
- Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
- Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study
- 18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma
- Standardization of Scanning for [18F]Fluorodeoxyglucose Positron Emission Tomography
- In Reply
- Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers
- Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor
- 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
- Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome
- [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung
- Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
- Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
- The role of clinical imaging in oncological drug development
- Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer
- Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
- Molecular Imaging of Metastatic Potential
- Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations
- Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas
- The role of FDG-PET scans in patients with lymphoma